Pfizer jab 97pc effective against symptomatic COVID: study

Pfizer/BioNTech’s coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97 percent, according to real-world evidence published Thursday by the pharmaceutical companies.

Using data from January 17 to March 6 from Israel’s national vaccination campaign, Pfizer/BioNTech found that prevention against asymptomatic disease also reached 94 percent.

An earlier real-world study using data from between December 20, 2020 and February 1, 2021 had showed effectiveness at preventing symptomatic disease at 94 percent and asymptomatic illness at 92 percent.

“This comprehensive real-world evidence … can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization declared COVID-19 a pandemic,” the two pharmaceutical companies said in a statement.

Israel’s inoculation campaign is the fastest in the world, with about 40 percent of the population already fully vaccinated against the virus.

Israel, which launched its vaccination campaign in December, has given the recommended two jabs of the Pfizer/BioNTech vaccine to just under four million of its roughly nine million people.

More than five million have received one shot.

“Incidence rates in the fully vaccinated population have massively dropped compared to the unvaccinated population, showing a marked decline in hospitalised cases due to COVID-19,” said Israel’s Ministry of Health director Yeheskel Levy.